此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations

2026年9月28日 更新者:Xentria, Inc.

Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients with Pulmonary Sarcoidosis with or Without Extrapulmonary Manifestations

研究概览

地位

主动,不招人

条件

研究类型

介入性

注册 (估计的)

32

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Aalborg、丹麦、9000
        • Xentria Investigative Site
      • Aarhus、丹麦、8200
        • Xentria Investigative Site
      • Odense、丹麦、5000
        • Xentria Investigative Site
      • Roskilde、丹麦、4000
        • Xentria Investigative Site
      • Vejle、丹麦、7100
        • Xentria Investigative Site
      • Prague、捷克语、140 59
        • Xentria Investigative Site
      • Bielsk Podlaski、波兰、15-044
        • Xentria Investigative Site
      • Lodz、波兰、90-153
        • Xentria Investigative Site
    • Alabama
      • Birmingham、Alabama、美国、35233
        • Xentria Investigative Site
    • Colorado
      • Denver、Colorado、美国、80206
        • Xentria Investigative Site
    • Florida
      • Jacksonville、Florida、美国、32209
        • Xentria Investigative Site
    • Illinois
      • Chicago、Illinois、美国、60611
        • Xentria Investigative Site
      • Chicago、Illinois、美国、60612
        • Xentria Investigative Site
    • Iowa
      • Iowa City、Iowa、美国、52242
        • Xentria Investigative Site
    • Maryland
      • Baltimore、Maryland、美国、21287
        • Xentria Investigative Site
    • Michigan
      • Detroit、Michigan、美国、48202
        • Xentria Investigative Site
    • Minnesota
      • Minneapolis、Minnesota、美国、55455
        • Xentria Investigative Site
    • New York
      • Albany、New York、美国、12208
        • Xentria Investigative Site
      • New York、New York、美国、10029
        • Xentria Investigative Site
    • North Carolina
      • Greenville、North Carolina、美国、27858
        • Xentria Investigative Site
    • Ohio
      • Cincinnati、Ohio、美国、45267
        • Xentria Investigative Site
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19140
        • Xentria Investigative Site
    • South Carolina
      • Charleston、South Carolina、美国、29425
        • Xentria Investigative Site
    • Virginia
      • Charlottesville、Virginia、美国、22903
        • Xentria Investigative Site
    • England
      • Coventry、England、英国、CV22DX
        • University Hospitals Coventry and Warwickshire NHS Trust
      • London、England、英国、SE59RS
        • King's College Hospital NHS Foundation Trust
      • London、England、英国、NW12PG
        • University College London Hospitals NHS Foundation Trust
      • Norwich、England、英国、NR47UY
        • Norfolk and Norwich University Hospitals NHS Foundation Trust
      • Oxford、England、英国、OX37LE
        • Oxford University Hospitals NHS Foundation Trust
    • Scotland
      • Perth、Scotland、英国、PH11NX
        • NHS Tayside
      • Barcelona、西班牙、08035
        • Xentria Investigative Site
      • Barcelona、西班牙、08036
        • Xentria Investigative Site
      • Seville、西班牙、41013
        • Xentria Investigative Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 80年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Participant between 18 to 80 years (inclusive) of age.
  2. Weighs between 45 kg and 160 kg (99 to 353 lbs) at Screening.
  3. Diagnosis of pulmonary sarcoidosis (at least 6 months before Screening) using the 2020 American Thoracic Society (ATS) Clinical Practice Guideline (Crouser et al, 2020), the European Respiratory Society (ERS) or the WASOG criteria including a compatible clinical and radiologic presentation with other causes of granulomatous disease ruled out (cutaneous and ocular involvement permitted).
  4. Modified Medical Research Conference (mMRC) Dyspnea Scale of ≥ 1.
  5. Receiving treatment of 7.5 to 25 mg/day of oral prednisone, or equivalent, during the screening period and, at the determination of the investigator, is capable of undergoing the protocol specific corticosteroid taper regimen.
  6. Receiving treatment with methotrexate, azathioprine, mycophenolate, leflunomide, chloroquine, or hydroxychloroquine for at least 3 months before Screening that has been at a stable dose for 4 weeks before Screening. All efforts should be made to maintain stable background therapy at the Screening dose through the intervention period at the Investigator's discretion.
  7. Willing to refrain from consumption of grapefruit or grapefruit juice [pomelos, exotic citrus fruits, or grapefruit hybrids] from screening visit until after the final dose.
  8. Polymerase chain reaction (PCR) test or rapid antigen test negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Screening.
  9. Able to provide written informed consent.
  10. In the opinion of the Investigator, the participant is capable of understanding and complying with protocol requirements

Exclusion Criteria:

  1. Pregnant or breastfeeding women or women who are planning to become pregnant during the study.

  2. Participants > 65 years of age. (This exclusion criterion is only applicable for EU).

  3. Known potentially significant fibrotic disease and/or active inflammation contained solely in the hilar region as shown by high-resolution computed tomography (HRCT), confirmed by a central reader. Participants with current active inflammation in the hilar region with concurrent inflammation outside the hilar region may be included.

    A historical HRCT performed within 6 months of screening may be submitted for diagnostic confirmation by central review. If a subject's last HRCT was from > 6 months of screening, an HRCT should be performed during screening for diagnostic confirmation by central review.

  4. Any prior TNFα inhibitor therapy.

  5. Clinically significant extra-pulmonary sarcoidosis requiring systemic therapy as determined by the investigator.

  6. Baseline percent predicted forced vital capacity (FVC) of < 50%.

  7. Prior treatment with rituximab or repository corticotropin injection within the previous 12 months.

  8. Clinically significant Central Nervous System (CNS) sarcoidosis requiring therapy, except history of isolated seventh cranial nerve palsy or evidence of demyelinating neurologic disease.

  9. Advanced congestive heart failure (New York Heart Association [NYHA] 3 or 4).

  10. Current disease presentation consistent with Lofgren's syndrome (i.e., presence of the triad of erythema nodosum, bilateral hilar lymphadenopathy on chest X-ray, and joint pain).

  11. Clinically significant pulmonary hypertension requiring treatment. Note: Clinically significant pulmonary hypertension requiring treatment would be defined as treatment with, i.e., prostacyclins, phosphodiesterase 5 inhibitors, and endothelin receptor antagonists.

  12. Known hypersensitivity to any component of the formulation of XTMAB-16.

  13. Live or messenger ribonucleic acid (mRNA) vaccination within 2 weeks before Day 1 or inoculation with a live or mRNA vaccine is planned during study participation.

  14. Evidence of active or latent TB by interferon-gamma release assay (IGRA) or invasive fungal infections at Screening.

  15. Known positive history of malignancy other than non-melanomatous skin cancer in the last 2 years, including in-situ carcinoma of the uterine cervix completely cured by radical surgery.

  16. Positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, coronavirus disease (COVID-19), TB, or a known history of human immunodeficiency virus (HIV) infection at Screening.

  17. Women of childbearing potential who are sexually active with a non-sterilized male partner and are not willing to adhere to highly effective birth control measures from the time of signing the informed consent, throughout the duration of the study, and for 90 days after 5 half-lives have elapsed since the last dose of study drug.

  18. Male participants who are non-sterilized and sexually active with a female partner of childbearing potential and are not willing to use highly effective contraception from the time of signing the informed consent throughout the duration of the study, and for 90 days after 5 half-lives have elapsed since last dose of study drug.

  19. Clinically significant hepatic or renal disease, including uncontrolled diabetes at the discretion of the investigator.

  20. Any severe prior reaction to any type of biologics or human blood product such as albumin, IgG, etc.

  21. Concurrent emphysema.

  22. Known hypercalcemia due to non-sarcoidosis conditions such as untreated hyperparathyroidism, at the discretion of the investigator.

  23. Abnormal ECG: ventricular arrhythmias (non-sustained ventricular tachycardia (VT), multifocal or frequent premature ventricular contractions, bundle branch block, axis deviation, or abnormal Q waves). In the case of a QTcF (corrected QT interval by Fredericia) interval > 450 ms (men) or > 480 ms (women; participants with bundle branch block) or PR interval outside the range of 120 to 220 ms, the assessment may be repeated once for eligibility determination at Screening or Baseline.

  24. Donation or loss of 450 mL or more of his or her blood volume (including plasmapheresis) or transfusion of any blood product within 90 days prior to dosing.

  25. Known uncontrolled hypertension. Note: Uncontrolled hypertension is noted as blood pressure ≥ 160/100 mmHg despite antihypertensive therapy within 3 months of randomization.

  26. Clinical signs and symptoms consistent with COVID-19, e.g., fever, dry cough, dyspnea, sore throat, fatigue, new smell or taste disorder or confirmed infection by appropriate laboratory test within the last 4 weeks prior to Screening.

  27. In the opinion of the investigator, inability to tolerate corticosteroid taper.

  28. Concurrent systemic steroid use for non-sarcoidosis conditions.

  29. Concurrent known auto-immune disease requiring treatment.

  30. Participation in another clinical trial of an investigational agent within 3 months (small molecule) / 6 months (biologics) or 5 half-lives (if known) of the agent, whichever is longer.

  31. Any condition that required hospitalization within the 3 months prior to Day 1 or is likely to require so during the study.

  32. Clinically significant abnormalities in the Screening physical exam, medical history, vital signs, ECG, or clinical laboratory tests that are not known to be due to concurrent sarcoidosis, and in the opinion of the Investigator and Medical Monitor should preclude the participant's participation in the clinical study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:顺序分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:A 部分 - XTMAB-16:每 4 周 (Q4W) 2 mg/kg,持续 12 周或安慰剂

Infusion

实验性的:A 部分 - XTMAB-16:每 4 周 (Q4W) 4 mg/kg,持续 12 周或安慰剂

Infusion

实验性的:A 部分 - XTMAB-16:每 2 周 (Q2W) 2 mg/kg,持续 12 周或安慰剂

Infusion

实验性的:A 部分 - XTMAB-16:每 2 周 (Q2W) 4 mg/kg,持续 12 周或安慰剂

Infusion

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Rate of Adverse Events (AEs), including Serious Adverse Events (SAEs), Dose Limiting Toxicities (DLTs), and Adverse Events of Special Interests (AESIs) throughout the study duration
大体时间:Throughout Study Duration, 20 weeks

To evaluate the safety and tolerability of multiple ascending doses of XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Throughout Study Duration, 20 weeks

次要结果测量

结果测量
措施说明
大体时间
Pharmacokinetic (PK) profile including trough concentration (Ctrough)
大体时间:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Pharmacokinetic (PK) profile including maximum concentration (Cmax)
大体时间:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Pharmacokinetic (PK) profile including average concentration (Caverage)
大体时间:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Pharmacokinetic (PK) profile including area under the curve (AUC)
大体时间:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Dose normalized maximum serum concentration (Cmax/D)
大体时间:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Dose normalized area under the concentration time curve over the dosing interval (AUCtau/D)
大体时间:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Dose normalized area under the concentration time curve from time 0 to the time of the last quantifiable concentration observed (AUClast/D)
大体时间:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Dose normalized area under the concentration time curve from time 0 extrapolated to infinity (AUCinf/D)
大体时间:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Pharmacodynamics (PD) markers, including: Angiotensin converting enzyme (ACE), Soluble IL-2 receptor (sIL 2R), C-reactive protein (CRP), Interleukin-1b (IL-1b) and Calcitriol (vitamin D 1, 25)
大体时间:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Occurrence and persistence of anti-drug antibodies (ADA)
大体时间:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Mean percent change in forced vital capacity (FVC)%
大体时间:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Change in King's Sarcoidosis Questionnaire (KSQ) - Lung Score
大体时间:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
The King's Sarcoidosis Questionnaire (KSQ) - General Health. Results are given as a number between 1 to 100 with higher numbers indicating better health. The minimal clinically important difference (MCID) for KSQ remains unclear in sarcoidosis.
大体时间:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
The Leicester Cough Questionnaire items are scored on a 7-point Likert scale. A total score (range 3 to 21) is also calculated by adding the domain scores together, with higher scores indicating better quality of life. The MCID for chronic cough is 1.3.
大体时间:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
The Steroid Toxicity Questionnaire (STQ) is a simple 12 question tool used to characterize the toxicity associated with steroid use using a 4-point scale. The MCID remains unclear in sarcoidosis. Higher scores indicate greater steroid toxicity
大体时间:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Observed dose limiting toxicities (DLT), rate of adverse events of special interest (AESI) throughout the study duration between dose levels and frequencies
大体时间:Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Proportion of participants who achieve the targeted tapered dose of corticosteroid
大体时间:Baseline to Week 12

To observe the potential therapeutic effect of XTMAB-16 as measured by the ability to reduce background oral corticosteroid use

Baseline to Week 12
Proportion of participants who achieve at least 50% reduction in dose of corticosteroid by Week 12
大体时间:Baseline to Week 12

To observe the potential therapeutic effect of XTMAB-16 as measured by the ability to reduce background oral corticosteroid use

Baseline to Week 12
Total (systemic) clearance after intravenous (IV) dose in the intended participant population
大体时间:Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Volume of distribution after intravenous (IV) dose and an estimate of the volume of distribution at steady state based on single dose IV data parameters in the intended participant population
大体时间:Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Terminal elimination phase half-life expressed in time units in the intended participant population
大体时间:Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Accumulation ratio repeat dosing
大体时间:Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Area under the effect-time curve from time 0 (predose) to the last quantifiable effect -concentration time point, t (AUEC0-t)
大体时间:Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Maximum observed effect (Emax, obs)
大体时间:Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Time to reach Emax, obs (tEmax, obs)
大体时间:Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Absolute and percent change in biomarkers from Baseline to End of Infusion (EOI), Interleukin-6 (IL-6) and Soluble Tumor Necrosis Factor α (sTNFα)
大体时间:Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Number and percentage of participants by cohort who test positive for XTMAB-16 anti-drug antibodies (ADA) and transient & persistent positive status at follow-up assessments
大体时间:Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Number and percentage of participants by cohort who test positive for XTMAB-16 neutralizing antibody (nAb) and transient & persistent positive status at follow-up assessments
大体时间:Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年11月10日

初级完成 (估计的)

2026年10月31日

研究完成 (估计的)

2026年10月31日

研究注册日期

首次提交

2023年5月12日

首先提交符合 QC 标准的

2023年5月25日

首次发布 (实际的)

2023年6月6日

研究记录更新

最后更新发布 (实际的)

2026年10月2日

上次提交的符合 QC 标准的更新

2026年9月28日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅